10x Genomics Collaborates with Dana-Farber on Tumor Sample Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy TXG?
10x Genomics announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples from patients with major solid cancer types to uncover biological features associated with treatment response, resistance and disease progression. The company also announced plans to establish a CLIA-certified laboratory. Together, these efforts mark the beginning of a multi-year research initiative to incorporate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TXG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TXG
Wall Street analysts forecast TXG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TXG is 13.00 USD with a low forecast of 9.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 17.700
Low
9.00
Averages
13.00
High
18.00
Current: 17.700
Low
9.00
Averages
13.00
High
18.00
About TXG
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Dataset Construction: PharosAI will utilize 10x Genomics' Xenium spatial platform to create one of the world's largest multimodal cancer datasets, backed by £18.9 million in government funding, aimed at accelerating early diagnosis and precision therapies.
- Technical Collaboration: The research consortium comprises four leading UK institutions, combining clinical expertise with advanced technologies, planning to transform thousands of clinical tissue samples into high-resolution datasets to drive breakthroughs in cancer research.
- AI Model Application: By integrating genomic, transcriptomic, and spatial biology data, PharosAI will develop custom AI models that reveal hidden patterns in cancer research, thereby enhancing patient care and treatment outcomes.
- Open Data Sharing: The initiative will ensure secure access to datasets for a broad community of researchers and innovators, positioning the UK at the forefront of AI-driven cancer research and advancing the field of precision medicine.
See More

- Partnership Announcement: PHAROS AI and 10X Genomics have formed a partnership to enhance cancer research through advanced genomic technologies.
- Focus on Spatial Biology: The collaboration aims to integrate spatial biology techniques to better understand cancer mechanisms and improve treatment strategies.
See More
- Historic Price Drop: On Friday, gold prices fell by 9.5% to $4,861 per ounce, while silver plummeted 27% to $84 per ounce, marking the largest single-day declines since 1980, leading to a sharp decrease in demand for precious metals and negatively impacting mining stocks.
- Mining Stocks Hit Hard: The collapse in gold and silver prices resulted in many mining stocks experiencing double-digit declines, reflecting a rapid loss of investor confidence in precious metals, prompting widespread sell-offs and putting pressure on the overall mining sector.
- Concerns Over Fed Independence Eased: The nomination of hawkish Kevin Warsh as the next Federal Reserve chair by President Trump has alleviated fears regarding the independence of the Fed, which may influence future monetary policy directions and investor sentiment.
- Increased Market Volatility: Warsh's criticism of modern monetary frameworks could inject new volatility into rate expectations; while this may promote short-term economic growth and employment, it also raises the risk of higher inflation in the long run.
See More
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
- AI Agents Theme: Ark Invest's first ARKmoji hints at agentic AI, with users divided on its meaning; the option 'AI Agent Takeover' received 37.5% support, indicating strong market interest in AI technologies that could impact stocks like Palantir.
- Genomics Potential: The second ARKmoji features a DNA helix, with 34.7% of votes for 'Molecular Diagnostics', highlighting investment opportunities in genomics, potentially benefiting related stocks like Crispr Therapeutics.
- Space Race Trend: The third ARKmoji depicts a rocket, with 55% of users selecting 'Reusable Rockets', reflecting enthusiasm for space technology investments, with holdings like Rocket Lab poised for growth.
- Robotics Development: The final ARKmoji shows a robot, with 59% voting for the 'Robotics' theme, indicating strong market interest in robotics technology, with Tesla's Optimus robot project likely to be a future growth driver.
See More

- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More








